Hite Christopher 4

What Happened

• Christopher Hite, EVP & Vice Chairman of Royalty Pharma (RPRX), received 26,626 Class A ordinary shares on 2026-02-11 as the settlement of equity performance awards. The shares were granted at $0.00 per share (total cash value reported: $0).

Key Details

• Transaction date: 2026-02-11; Filing date (Form 4): 2026-02-13.
• Transaction type: Award/Grant (Code A); acquisition exempt under Rule 16b-3 related to settlement of Equity Performance Awards (Footnote F1).
• Price and value: 26,626 shares at $0.00 per share — cash value shown as $0.
• Shares owned after transaction: Not specified in the filing.
• Timeliness: Filing appears timely (no late filing indicator reported).

Context

• This was a settled equity award (not an open-market purchase or sale), so it reflects compensation/award settlement rather than a market trade by the insider.
• The filing notes that family vehicles controlled by Hite hold exchangeable interests equal to 866,410 Class A shares (RPI US Partners 2019, LP) and Class E shares of RPH exchangeable into 1,238,789 Class A shares of Royalty Pharma Holdings Ltd; the Class E shares are subject to vesting conditions.